# Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

> **NCT01639339** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc., a GSK Company** · enrollment: 448 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** Placebo plus standard therapy
- **BIOLOGICAL:** Belimumab 10 mg/kg plus standard therapy
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT01639339
- **Lead sponsor:** Human Genome Sciences Inc., a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-12
- **Primary completion:** 2019-07-25
- **Final completion:** 2020-03-12
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639339, "Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01639339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*